Shamburg News · 8-K filed Oct 5, 2026, 5:06 PM EDT

Equillium Receives Australian Ethics and TGA Clearance for EQ504 Phase 1 Trial

EQ · Equillium, Inc.

  • Other event
  • Materiality: medium

Equillium, Inc. announced on October 5, 2026 that it received Human Research Ethics Committee approval and Therapeutic Goods Administration clearance in Australia under the Clinical Trial Notification scheme for its Phase 1 trial of EQ504. The randomized, double-blinded, placebo-controlled single-center study in healthy participants will explore once-daily oral doses from 0.1 to 3.0 mg across single ascending dose, multiple ascending dose, and food effect cohorts. The company expects to begin dosing healthy participants by early November 2026.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 8.01, accession 0001193125-26-414364.

Written from the filing by Shamburg Markets. Figures are as reported by the company.